Skip to main content
. Author manuscript; available in PMC: 2019 Mar 8.
Published in final edited form as: Sci Transl Med. 2016 Nov 23;8(366):366ra163. doi: 10.1126/scitranslmed.aaf1090

Fig 6. Treatment with an ACVR1-selective kinase inhibitor prevents HO in global knock-in Acvr1R206H mice in vivo.

Fig 6.

Rosa-CreERT2:Acvr1[R206H]FlEx/+mice treated with tamoxifen for 10–12 wks, followed by treatment with vehicle for 4 wks developed spontaneous joint and ligamentous HO, as well as prominent interscapular HO at sites of handling and examination (red arrows, top panels), whereas animals treated with the ACVR1-selective inhibitor LDN-212854 (2.5 mg/kg twice daily s.c.) demonstrated near-complete inhibition of joint, ligamentous, and interscapular HO (red arrow, lower panel).